Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTKNASDAQ:KRYSNYSE:OGNNYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$33.90-1.3%$33.28$29.31▼$61.38$4.14B0.591.52 million shs1.30 million shsKRYSKrystal Biotech$143.01+1.2%$138.57$122.80▼$219.34$4.13B0.67287,155 shs168,281 shsOGNOrganon & Co.$10.08-0.7%$9.61$8.01▼$23.10$2.59B0.63.54 million shs2.38 million shsRCUSArcus Biosciences$8.47-1.5%$8.83$6.50▼$18.98$896.85M0.8879,840 shs297,205 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics-1.34%-0.03%+5.94%-9.26%-37.68%KRYSKrystal Biotech+1.17%+0.30%+9.24%-16.51%-19.46%OGNOrganon & Co.-0.84%+0.88%+6.78%-22.71%-50.42%RCUSArcus Biosciences-1.46%-0.70%-15.60%+23.22%-41.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTKCytokinetics3.9452 of 5 stars4.52.00.04.60.00.80.0KRYSKrystal Biotech4.5893 of 5 stars3.51.00.04.72.82.51.9OGNOrganon & Co.4.8251 of 5 stars3.34.01.73.71.73.31.9RCUSArcus Biosciences2.8568 of 5 stars4.43.00.00.00.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.93Moderate Buy$70.92109.21% UpsideKRYSKrystal Biotech 3.00Buy$211.1347.63% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0078.66% UpsideRCUSArcus Biosciences 2.89Moderate Buy$21.29151.46% UpsideCurrent Analyst Ratings BreakdownLatest RCUS, CYTK, KRYS, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.006/9/2025CYTKCytokineticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.005/29/2025CYTKCytokineticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/14/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.005/13/2025CYTKCytokineticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025RCUSArcus BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.005/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.005/8/2025RCUSArcus BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$18.47M219.20N/AN/A($1.15) per share-29.48KRYSKrystal Biotech$290.52M14.23$4.64 per share30.85$32.90 per share4.35OGNOrganon & Co.$6.40B0.41$4.99 per share2.02$1.83 per share5.51RCUSArcus Biosciences$258M3.47N/AN/A$5.30 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1634.3814.19N/A37.17%14.64%13.28%8/4/2025 (Estimated)OGNOrganon & Co.$864M$2.883.502.691.0411.92%227.43%7.34%8/5/2025 (Estimated)RCUSArcus Biosciences-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)Latest RCUS, CYTK, KRYS, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.79%N/A2.78%N/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ALatest RCUS, CYTK, KRYS, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A5.995.99KRYSKrystal BiotechN/A9.659.27OGNOrganon & Co.16.491.671.15RCUSArcus Biosciences0.095.375.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AKRYSKrystal Biotech86.29%OGNOrganon & Co.77.43%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.70%KRYSKrystal Biotech13.70%OGNOrganon & Co.1.96%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250119.43 million116.20 millionOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableOGNOrganon & Co.4,000259.96 million254.86 millionNot OptionableRCUSArcus Biosciences500105.89 million95.72 millionOptionableRCUS, CYTK, KRYS, and OGN HeadlinesRecent News About These CompaniesArcus Biosciences (NYSE:RCUS) Trading Down 2.9% - Here's What HappenedJuly 3 at 1:13 PM | marketbeat.comArcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer TreatmentJuly 1 at 4:07 AM | msn.comArcus Biosciences (NYSE:RCUS) Trading Down 6.3% - Here's What HappenedJune 27, 2025 | marketbeat.comIncyte, FDA, Sun Pharma and more—Chutes & LaddersJune 27, 2025 | fiercebiotech.comFArcus Biosciences Announces New Employment Inducement Grants - Business WireJune 26, 2025 | businesswire.comPrecision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’June 26, 2025 | msn.comBrokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $24.13June 26, 2025 | americanbankingnews.comPrecision BioSciences Shares Surge Following FDA Rare Pediatric Disease DesignationJune 25, 2025 | msn.comPrecision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%June 25, 2025 | msn.comArcus Biosciences, Inc. (RCUS) Cash Flow - Yahoo FinanceJune 24, 2025 | finance.yahoo.comRCUS Arcus Biosciences, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comArcus Biosciences Announces New Employment Inducement GrantsJune 24, 2025 | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by AnalystsJune 23, 2025 | marketbeat.comThe trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gambleJune 13, 2025 | fiercebiotech.comFArcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?June 11, 2025 | marketbeat.comStock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)June 11, 2025 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsJune 10, 2025 | businesswire.comResearch Analysts Offer Predictions for RCUS FY2026 EarningsJune 10, 2025 | marketbeat.comH.C. Wainwright maintains Buy rating for Arcus Biosciences stockJune 4, 2025 | investing.comArcus Biosciences, Inc. (NYSE:RCUS) Short Interest Up 25.2% in MayJune 4, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Trading 10.6% Higher - Here's What HappenedJune 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCUS, CYTK, KRYS, and OGN Company DescriptionsCytokinetics NASDAQ:CYTK$33.90 -0.46 (-1.34%) Closing price 07/3/2025 02:25 PM EasternExtended Trading$34.52 +0.62 (+1.81%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$143.01 +1.66 (+1.17%) Closing price 07/3/2025 03:17 PM EasternExtended Trading$146.50 +3.49 (+2.44%) As of 07/3/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Organon & Co. NYSE:OGN$10.07 -0.08 (-0.74%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$10.06 -0.02 (-0.20%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Arcus Biosciences NYSE:RCUS$8.46 -0.13 (-1.46%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$8.46 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
